Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses
This study demonstrates the potential utility of ultrasensitive detection of ctDNA as a predictive and prognostic marker of disease progression and OS in LACC independent of disease stage.
Authors
- Zsuzsanna Kahán (ORCID: https://orcid.org/0000-0002-5021-8775)
- Francisco Javier Ramírez Godinez
- Bradley J. Monk (ORCID: https://orcid.org/0000-0001-6985-0159)
- Francisco Acevedo (ORCID: https://orcid.org/0000-0003-3482-7746)
- Maria A.S. Broggi (ORCID: https://orcid.org/0000-0001-7909-5097)
- A. Molina Alavez
- Felipe Rey
- Angélica Figueroa (ORCID: https://orcid.org/0000-0001-5530-5213)
- A Santini
- Pedro Pablo Galaz
- Lucely Cetina (ORCID: https://orcid.org/0000-0003-2018-7338)
- María Trinidad García Leiva (ORCID: https://orcid.org/0000-0001-8572-0565)
- Lara Vera
- Juan Carlos Vázquez Limón
- Jyoti Mayadev (ORCID: https://orcid.org/0000-0003-4786-8192)
- Masaki Mandai (ORCID: https://orcid.org/0000-0003-4428-8029)
- Štefan Varga (ORCID: https://orcid.org/0000-0003-1626-1507)
- Natalia Valdiviezo (ORCID: https://orcid.org/0000-0002-4300-5958)
- Wenjing Xin
- Ashley E. Alarcon-Rozas (ORCID: https://orcid.org/0000-0002-3242-4102)
- Ronnie Shapira‐Frommer (ORCID: https://orcid.org/0000-0001-6170-080X)
- H. Dry
- Maria Del Pilar Estevez-Diz (ORCID: https://orcid.org/0000-0003-3176-9747)
- Sewanti Limaye (ORCID: https://orcid.org/0000-0001-6640-1470)
- Guillermo Meléndez (ORCID: https://orcid.org/0000-0003-2992-6395)
- Dongya Yuan (ORCID: https://orcid.org/0000-0002-3480-5283)
- Xiaohua Wu (ORCID: https://orcid.org/0000-0002-2271-2514)
- Robyn Stewart
Institutions
- AstraZeneca (United Kingdom) (GB)
- Universidad de La Frontera (CL)
- Universidad de Antofagasta (CL)
- International Potato Center (PE)
- Universidad Autónoma de Nuevo León (MX)
- Kyoto University (JP)
- University of Szeged (HU)
- Sir H.N. Reliance Foundation Hospital and Research Centre (IN)
- Sheba Medical Center (IL)
- Universidad Católica de Temuco (CL)
- Instituto do Câncer do Estado de São Paulo (BR)
- AstraZeneca (South Korea) (KR)
- Hospital Nacional Cayetano Heredia (PE)
- Fudan University Shanghai Cancer Center (CN)
- Instituto de Radiomedicina (CL)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Brazil) (BR)
- Florida Cancer Specialists & Research Institute (US)
- Beatrix Kinderziekenhuis (NL)
- National Institute of Oncology (HU)
- Universidad Ricardo Palma (PE)
- Hospital Civil de Guadalajara (MX)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Forum Solidaridad Perú (PE)
- University of California San Diego Medical Center (US)
- AstraZeneca (Finland) (FI)
- Vietnam National Children's Hospital (VN)
- AstraZeneca (United States) (US)
- Instituto Nacional de Cancerología (MX)
- Universidad Marista de Mérida (MX)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1016/j.annonc.2025.05.533
- Citations
- 11
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 10.30
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Karyopharm Therapeutics
- Array BioPharma
- Varian Medical Systems
- Regeneron Pharmaceuticals
- Novocure
- Clovis Oncology
- Mersana Therapeutics
- NRG Oncology
- NuCana
- Puma Biotechnology
- MacroGenics
- Eisai
- Russian Science Foundation
- Ipsen
- Genentech